Navigation Links
Andrew P. Mandell - Mr. Diabetes(R) to Sit On ProtoKinetix Advisory Board
Date:1/15/2010

MADEIRA BEACH, Fla., Jan. 15 /PRNewswire/ -- Andrew P. Mandell – Mr. Diabetes®, Executive Director of Defeat Diabetes Foundation and diabetes advocate announced today that he will be sitting on the ProtoKinetix (PKTX) Advisory Board.  ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGP™) for medicine and the biotechnology and cosmetic industries.

"I'm really excited about their technology and it's potential to offer the first truly viable long term treatment for diabetes," said Mandell. "The Protokinetix's research team has made remarkable progress in the harvesting and preservation of stem cells for islet transplantation for diabetes treatments," he continued.

"In addition to the potential treatments for diabetes, AAGP™ also shows great promise in many other medical applications. I'm really looking forward to contributing where I can to support their work," Mandell concluded.

Defeat Diabetes Foundation

Defeat Diabetes Foundation is a 501(c)(3) nonprofit  whose mission is the prevention, early identification and effective self management of diabetes.

DDF has awareness and interactive programs in all 50 states to provide critical information and education programs with a focus on diabetes, nutrition and physical fitness. Their public information programs include the KIDD™ Project which has provided millions of Free Defeat Diabetes® Screening Test brochures to schools in all 50 states, the DAN Project, a Public Service Announcements program and the Martial Arts Defeat Diabetes® Community Action Project (MADDCAP™) a historic health curriculum for martial arts schools and their students.

For information on diabetes, to take the free screening test or obtain additional information visit: www.DefeatDiabetes.org

For information on ProtoKinetix visit the website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

SOURCE Defeat Diabetes Foundation

RELATED LINKS
http://www.defeatdiabetes.org/
http://www.protokinetix.com/

'/>"/>

SOURCE Defeat Diabetes Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vical Names Andrew de Guttadauro Vice President, Corporate Development
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
4. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Algeta Appoints Andrew Kay as President and Chief Executive Officer
7. Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
8. Veridiam Appoints Andrew Gale as Chief Executive Officer
9. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
10. Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club
11. ProtoKinetix Partners with OTC Financial Network to Increase Shareholder Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):